Patented light-activated Photo Dynamic Compounds ("PDCs") have been clinically proven to destroy NMIBC and allow patients to achieve a complete response (cancer-free)
Phase II NMIBC clinical study is in progress with University Health Network ("UHN") ( Toronto, Ontario), McGill University Health Centre ("MUHC") (Montreal, Quebec), London Health Sciences Centre ("LHSC")( London, Ontario) and Nova Scotia Health Authority ("NSHA") (Halifax, Nova Scotia) currently enrolling and treating patients. This clinical study sites have successfully enrolled and treated 12 patients in a planned 100 patient pivotal Phase II clinical study.
Our experienced management team has partnered with leading scientific and clinical researchers from renowned research hospitals and academic institutions to develop cutting-edge technologies to destroy cancer and eliminate pain.
Theralase®’s patented TLD-1433 PDC has successfully completed a Phase 1b NMIBC clinical study demonstrating strong safety and a 67% Complete Response rate.
For over 25 years, Theralase® has focused on the research, development and commercialization of patented and proprietary laser technologies.
Theralase® has been issued 27 patents for its technology and has an additional 27 patents pending.
Data last updated on October 1, 2020
- TSX Venture Exchange (TSXV: TLT)
- Over-The-Counter Exchange (OTCQB: TLTFF)
Share Price: C$0.14
Shares Outstanding: 204,275,375
Stock Options: 14,500,000
Fully Diluted: 291,249,306
For Investor Relations please contact: Investor Information Theralase®